查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1494900

到 2030 年疫苗佐剂市场预测：按佐剂类型、疾病类型、疫苗类型、给药途径、应用、最终用户和地区进行的全球分析

Vaccine Adjuvants Market Forecasts to 2030 - Global Analysis By Adjuvant Type (Alum, Liposomes, Viral-Derived Particles and Other Adjuvants Types), Disease Type, Vaccine Type, Route of Administration, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2024年全球疫苗佐剂市场规模将达8亿美元，预计2030年将达到14亿美元，预测期内复合年增长率为8.9%。

疫苗佐剂是一种添加到疫苗中以增强对疫苗抗原的免疫反应的物质。佐剂有助于产生更强、更持久的免疫反应，减少抗原的量和免疫所需的剂量数量。佐剂包括活化免疫系统的活化和更有效地将抗原呈现给免疫细胞的递送系统。

根据世界卫生组织（WHO）报告，全球人类疫苗市场从2000年的60亿美元成长到2014年的330亿美元和2018年的364.5亿美元，其中高所得国家的销售额约占65%的总销售额。

感染疾病增加

随着全球感染疾病负担持续增加，越来越需要有效的疫苗来预防和控制这些疾病。佐剂在提高疫苗的免疫抗原性和功效方面发挥重要作用，使疫苗更有效、更持久。流感、疟疾、结核病等感染疾病以及 COVID-19 等新出现的病原体的高流行进一步加速了对佐剂疫苗的需求。因此，感染疾病的传播增加了对疫苗佐剂的需求，推动市场成长。

开发和製造成本高

疫苗佐剂的高开发和製造成本是市场的主要限制因素。开发过程复杂且耗时，需要在研发、生产设施和专业知识方面进行大量投资。疫苗开发可能需要数年时间并且成本高昂。高故障率挑战製造商获得资金并支付营运成本。

新疫苗的开发

随着研究人员致力于开发针对爱滋病毒、疟疾和癌症等挑战性疾病的疫苗，越来越需要强大的佐剂来提高这些疫苗的有效性。新型佐剂可刺激更强、更有针对性的免疫反应，减少所需抗原的量，并使新的疫苗递送方法的使用成为可能。对皂素、TLR促效剂、奈米粒子和黏膜佐剂等佐剂的持续研究预计将导致更有效和创新的疫苗的开发。对新疫苗和改进疫苗的需求不断增长预计将推动未来几年疫苗佐剂市场的成长。

严格的监管要求

严格的监管要求对市场构成重大威胁，因为新助剂的核准过程既耗时又昂贵。要满足 FDA 和 EMA 等监管机构制定的严格安全性和有效性标准，需要大量的临床前和临床资料，从而延长产品开发时间。此外，监管障碍和核准延迟可能会阻碍市场进入并限制创新。遵守复杂的法律规范会为企业带来经济负担和不确定性，影响竞争力和市场成长。

COVID-19 的影响：

COVID-19大流行对疫苗佐剂市场产生了积极影响。随着研究人员探索不同的配方来增强对病毒的免疫反应，对有效疫苗的迫切需求推动了佐剂技术的进步。因此，疫情期间佐剂的需求增加，且这一趋势预计将持续下去。这场危机加速了佐剂的创新和发现，对未来的疫苗开发有广泛的影响。

在预测期内，感染疾病领域预计将是最大的。

由于全球感染疾病发病率不断上升以及对有效疫苗的迫切需求，预计感染疾病领域将在预测期内主导疫苗佐剂市场。这一增长是由政府对免疫计划的承诺和资金的增加以及提高疫苗功效的佐剂技术的进步所推动的。此外，感染疾病预防意识的提高以及针对新出现病原体的疫苗开发的进展也有助于该领域的主导地位。

预计肌肉注射领域在预测期内复合年增长率最高。

预计在预测期内，肌肉注射细分市场将成为疫苗佐剂市场中复合年增长率最高的领域。这是因为肌肉注射是最常见的疫苗接种方法，可以有效地将疫苗输送到血液供应丰富且含有对疫苗快速反应的免疫细胞的肌肉组织。与皮下或皮内给药相比，肌肉给药也降低了局部反应的风险。此外，强烈建议将许多含有佐剂的疫苗进行肌肉注射，以优化免疫抗原性并最大限度地减少副作用。

占比最大的地区：

由于亚太地区人口众多、感染疾病流行率不断上升以及人们对疫苗接种益处的认识不断增强，预计亚太地区将占据疫苗佐剂市场的最高市场占有率。此外，政府措施、对医疗基础设施的投资、主要市场参与者的存在以及不断扩大的生物製药产业都有助于市场成长。除了该地区对创新研发的重视外，有利的法规环境也进一步拉动了亚太地区对疫苗佐剂的需求。

复合年增长率最高的地区：

由于先进的医疗基础设施、积极的研发活动以及对疫苗开发的高投资，预计北美在预测期内将在疫苗佐剂市场中表现出最高的复合年增长率。该地区受益于政府的大力支持、有利的法规结构以及感染疾病的高流行，推动了对有效疫苗的需求。此外，大型生物製药公司的存在以及人们对疫苗接种重要性的认识不断提高也促进了北美市场的快速成长。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球疫苗佐剂市场：按佐剂类型

  • 明矾（氢氧化铝）
  • 脂质体
  • 病毒衍生颗粒 (VDP)
  • 乳液
  • 碳水化合物佐剂
  • 张力活性佐剂
  • 有机佐剂
  • 矿物盐类佐剂
  • 其他佐剂类型

第六章全球疫苗佐剂市场：依疾病类型

  • 感染疾病
  • 癌症
  • 其他疾病类型

第七章全球疫苗佐剂市场：依疫苗类型

  • 病毒疫苗
  • 细菌疫苗
  • 寄生虫疫苗
  • 其他疫苗类型

第八章全球疫苗佐剂市场：依给药途径

  • 肌肉注射
  • 皮下的
  • 鼻腔
  • 口服
  • 皮内

第九章全球疫苗佐剂市场：依应用分类

  • 研究用途
  • 商业用途

第10章全球疫苗佐剂市场：依最终用户分类

  • 人类疫苗佐剂
  • 兽用疫苗佐剂

第十一章全球疫苗佐剂市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司概况

  • GlaxoSmithKline plc（GSK）
  • CSL Limited
  • Novavax, Inc.
  • SPI Pharma, Inc.
  • Seppic（Air Liquide）
  • Invivogen
  • Croda International Plc
  • Dynavax Technologies Corporation
  • Adjuvance Technologies Inc.
  • Agenus Inc.
  • OZ Biosciences
  • Avanti Polar Lipids, Inc.
  • MVP Laboratories, Inc.
  • Vaxine Pty Ltd
  • GlycoMira Therapeutics Inc.
  • Pfizer Inc.
  • Sanofi
  • Merck & Co., Inc.
  • Zoetis Inc.
  • Moderna, Inc.
Product Code: SMRC26420

According to Stratistics MRC, the Global Vaccine Adjuvants Market is accounted for $0.8 billion in 2024 and is expected to reach $1.4 billion by 2030 growing at a CAGR of 8.9% during the forecast period. Vaccine adjuvants are substances added to vaccines to enhance the immune response to the vaccine antigen. They help create a stronger and longer-lasting immune response, reducing the amount of antigen needed and the number of doses required for immunity. Adjuvants can be immunostimulants that activate the immune system or delivery systems that present the antigen more effectively to immune cells.

According to a report by the World Health Organization (WHO), the global human vaccine market grew from USD 6 billion in 2000 to USD 33 billion in 2014 and USD 36.45 billion in 2018, with sales to high-income countries representing about 65% of the total value.

Market Dynamics:

Driver:

Rising prevalence of infectious diseases

As the global burden of infectious diseases continues to grow, there is an increasing demand for effective vaccines to prevent and control these diseases. Adjuvants play a crucial role in enhancing the immunogenicity and efficacy of vaccines, making them more potent and long-lasting. The high incidence rates of infectious diseases such as influenza, malaria, tuberculosis, and emerging pathogens like COVID-19 have further accelerated the need for adjuvanted vaccines. Consequently, the growing prevalence of infectious diseases is propelling the demand for vaccine adjuvants and driving market growth.

Restraint:

High cost of development and manufacturing

The high cost of developing and manufacturing vaccine adjuvants is a significant restraint in the market. The development process is complex, time-consuming, and requires substantial investment in research and development, production facilities, and specialized knowledge. Vaccine development can take a few years, and it comes at a high cost. The high failure rate makes it challenging for manufacturers to secure funds and cover operational expenses.

Opportunity:

Development of new vaccines

As researchers work on vaccines for challenging diseases like HIV, malaria, and cancer, there is a growing need for potent adjuvants to enhance the efficacy of these vaccines. Novel adjuvants can help stimulate stronger and more targeted immune responses, reduce the amount of antigen required, and enable the use of new vaccine delivery methods. Ongoing research into adjuvants such as saponins, TLR agonists, nanoparticles, and mucosal adjuvants holds promise for the development of more effective and innovative vaccines. The increasing demand for new and improved vaccines is expected to drive the growth of the vaccine adjuvant market in the coming years.

Threat:

Stringent regulatory requirements

Stringent regulatory requirements pose a significant threat to the market due to the lengthy and costly approval processes for new adjuvants. Meeting stringent safety and efficacy standards set by regulatory authorities such as the FDA and EMA requires extensive preclinical and clinical data, prolonging product development timelines. Additionally, any regulatory hurdles or delays in approvals can hinder market entry and limit innovation. Adhering to complex regulatory frameworks adds financial burden and uncertainty for companies, impacting their competitiveness and market growth.

Covid-19 Impact:

The COVID-19 pandemic had a positive impact on the vaccine adjuvants market. The urgent need for effective vaccines drove advancements in adjuvant technologies as researchers explored various formulations to enhance immune responses against the virus. This led to increased demand for adjuvants during the pandemic, with the trend expected to persist in the coming years. The crisis accelerated innovations and discoveries in adjuvants that have broader implications for future vaccine development.

The infectious diseases segment is expected to be the largest during the forecast period

The infectious diseases segment is expected to be the largest in the vaccine adjuvants market during the forecast period due to the rising incidence of infectious diseases globally and the urgent need for effective vaccines. Increasing government initiatives and funding for immunization programs, coupled with advancements in adjuvant technology enhancing vaccine efficacy, are driving this growth. Furthermore, heightened awareness of infectious disease prevention and the ongoing development of vaccines targeting emerging pathogens contribute to the dominance of this segment.

The intramuscular segment is expected to have the highest CAGR during the forecast period

The intramuscular segment is expected to have the highest CAGR in the vaccine adjuvants market during the forecast period. This is because intramuscular injection is the most common method of vaccine administration, as it allows for efficient delivery of the vaccine to the muscle tissue, which has a rich blood supply and contains immune cells that can quickly respond to the vaccine. Intramuscular administration also reduces the risk of local reactions compared to subcutaneous or intradermal routes. Furthermore, many vaccines containing adjuvants are strongly preferred to be administered intramuscularly to optimize immunogenicity and minimize adverse reactions.

Region with largest share:

The Asia Pacific is projected to hold the highest market share in the vaccine adjuvant market due to its large population, increasing prevalence of infectious diseases, and rising awareness about vaccination benefits. Additionally, government initiatives and investments in healthcare infrastructure, coupled with the presence of key market players and an expanding biopharmaceutical industry, contribute to market growth. The region's focus on innovative research and development, along with favorable regulatory environments, further drives the demand for vaccine adjuvants in Asia Pacific region.

Region with highest CAGR:

North America is expected to exhibit the highest CAGR in the vaccine adjuvants market during the forecast period due to advanced healthcare infrastructure, robust R&D activities, and significant investments in vaccine development. The region benefits from strong government support, favorable regulatory frameworks, and a high prevalence of infectious diseases, driving the demand for effective vaccines. Additionally, the presence of leading biopharmaceutical companies and increasing awareness about vaccination's importance contribute to the rapid market growth in North America.

Key players in the market

Some of the key players in Vaccine Adjuvants Market include GlaxoSmithKline plc (GSK), CSL Limited, Novavax, Inc., SPI Pharma, Inc., Seppic (Air Liquide), Invivogen, Croda International Plc, Dynavax Technologies Corporation, Adjuvance Technologies Inc., Agenus Inc., OZ Biosciences, Avanti Polar Lipids, Inc., MVP Laboratories, Inc., Vaxine Pty Ltd, GlycoMira Therapeutics Inc., Pfizer Inc., Sanofi Merck & Co., Inc., Zoetis Inc. and Moderna, Inc.

Key Developments:

In May 2024, Novavax and Sanofi announced a co-exclusive licensing agreement to co-commercialize Novavax's COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines. The deal allows Sanofi to use Novavax's COVID-19 shot and flagship vaccine technology, Matrix-M adjuvant, to develop new vaccine products.

In October 2023, SPI Pharma, Inc. signed a distribution partnership with Q-Vant Biosciences, Inc. The partnership involves the development of Q-Vant's Q-SAP saponin adjuvant technology. The partnership would provide saponin adjuvants to vaccine developers and manufacturers globally.

In July 2023, CSL Seqirus, a business of CSL announced it has begun to ship its portfolio of innovative cell-based, adjuvanted and egg-based influenza vaccines across the U.S. in preparation for the 2023/24 influenza season. The company is positioned to supply over 55 million doses of influenza vaccines to healthcare providers across the U.S.

Adjuvants Types Covered:

  • Alum (Aluminum Hydroxide)
  • Liposomes
  • Viral-Derived Particles (VDPs)
  • Emulsions
  • Carbohydrate Adjuvants
  • Tensoactive Adjuvants
  • Organic Adjuvants
  • Mineral Salt-Based Adjuvants
  • Other Adjuvants Types

Disease Types Covered:

  • Infectious Diseases
  • Cancer
  • Other Disease Types

Vaccine Types Covered:

  • Viral Vaccines
  • Bacterial Vaccines
  • Parasitic Vaccines
  • Other Vaccine Types

Route of Administration Covered:

  • Intramuscular
  • Subcutaneous
  • Intranasal
  • Oral
  • Intradermal

Applications Covered:

  • Research Application
  • Commercial Application

End Users Covered:

  • Human Vaccine Adjuvants
  • Veterinary Vaccine Adjuvants

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Vaccine Adjuvants Market, By Adjuvant Type

  • 5.1 Introduction
  • 5.2 Alum (Aluminum Hydroxide)
  • 5.3 Liposomes
  • 5.4 Viral-Derived Particles (VDPs)
  • 5.5 Emulsions
  • 5.6 Carbohydrate Adjuvants
  • 5.7 Tensoactive Adjuvants
  • 5.8 Organic Adjuvants
  • 5.9 Mineral Salt-Based Adjuvants
  • 5.10 Other Adjuvants Types

6 Global Vaccine Adjuvants Market, By Disease Type

  • 6.1 Introduction
  • 6.2 Infectious Diseases
  • 6.3 Cancer
  • 6.4 Other Disease Types

7 Global Vaccine Adjuvants Market, By Vaccine Type

  • 7.1 Introduction
  • 7.2 Viral Vaccines
  • 7.3 Bacterial Vaccines
  • 7.4 Parasitic Vaccines
  • 7.5 Other Vaccine Types

8 Global Vaccine Adjuvants Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Intramuscular
  • 8.3 Subcutaneous
  • 8.4 Intranasal
  • 8.5 Oral
  • 8.6 Intradermal

9 Global Vaccine Adjuvants Market, By Application

  • 9.1 Introduction
  • 9.2 Research Application
  • 9.3 Commercial Application

10 Global Vaccine Adjuvants Market, By End User

  • 10.1 Introduction
  • 10.2 Human Vaccine Adjuvants
  • 10.3 Veterinary Vaccine Adjuvants

11 Global Vaccine Adjuvants Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 GlaxoSmithKline plc (GSK)
  • 13.2 CSL Limited
  • 13.3 Novavax, Inc.
  • 13.4 SPI Pharma, Inc.
  • 13.5 Seppic (Air Liquide)
  • 13.6 Invivogen
  • 13.7 Croda International Plc
  • 13.8 Dynavax Technologies Corporation
  • 13.9 Adjuvance Technologies Inc.
  • 13.10 Agenus Inc.
  • 13.11 OZ Biosciences
  • 13.12 Avanti Polar Lipids, Inc.
  • 13.13 MVP Laboratories, Inc.
  • 13.14 Vaxine Pty Ltd
  • 13.15 GlycoMira Therapeutics Inc.
  • 13.16 Pfizer Inc.
  • 13.17 Sanofi
  • 13.18 Merck & Co., Inc.
  • 13.19 Zoetis Inc.
  • 13.20 Moderna, Inc.

List of Tables

  • Table 1 Global Vaccine Adjuvants Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Vaccine Adjuvants Market Outlook, By Adjuvant Type (2022-2030) ($MN)
  • Table 3 Global Vaccine Adjuvants Market Outlook, By Alum (Aluminum Hydroxide) (2022-2030) ($MN)
  • Table 4 Global Vaccine Adjuvants Market Outlook, By Liposomes (2022-2030) ($MN)
  • Table 5 Global Vaccine Adjuvants Market Outlook, By Viral-Derived Particles (VDPs) (2022-2030) ($MN)
  • Table 6 Global Vaccine Adjuvants Market Outlook, By Emulsions (2022-2030) ($MN)
  • Table 7 Global Vaccine Adjuvants Market Outlook, By Carbohydrate Adjuvants (2022-2030) ($MN)
  • Table 8 Global Vaccine Adjuvants Market Outlook, By Tensoactive Adjuvants (2022-2030) ($MN)
  • Table 9 Global Vaccine Adjuvants Market Outlook, By Organic Adjuvants (2022-2030) ($MN)
  • Table 10 Global Vaccine Adjuvants Market Outlook, By Mineral Salt-Based Adjuvants (2022-2030) ($MN)
  • Table 11 Global Vaccine Adjuvants Market Outlook, By Other Adjuvants Types (2022-2030) ($MN)
  • Table 12 Global Vaccine Adjuvants Market Outlook, By Disease Type (2022-2030) ($MN)
  • Table 13 Global Vaccine Adjuvants Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 14 Global Vaccine Adjuvants Market Outlook, By Cancer (2022-2030) ($MN)
  • Table 15 Global Vaccine Adjuvants Market Outlook, By Other Disease Types (2022-2030) ($MN)
  • Table 16 Global Vaccine Adjuvants Market Outlook, By Vaccine Type (2022-2030) ($MN)
  • Table 17 Global Vaccine Adjuvants Market Outlook, By Viral Vaccines (2022-2030) ($MN)
  • Table 18 Global Vaccine Adjuvants Market Outlook, By Bacterial Vaccines (2022-2030) ($MN)
  • Table 19 Global Vaccine Adjuvants Market Outlook, By Parasitic Vaccines (2022-2030) ($MN)
  • Table 20 Global Vaccine Adjuvants Market Outlook, By Other Vaccine Types (2022-2030) ($MN)
  • Table 21 Global Vaccine Adjuvants Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 22 Global Vaccine Adjuvants Market Outlook, By Intramuscular (2022-2030) ($MN)
  • Table 23 Global Vaccine Adjuvants Market Outlook, By Subcutaneous (2022-2030) ($MN)
  • Table 24 Global Vaccine Adjuvants Market Outlook, By Intranasal (2022-2030) ($MN)
  • Table 25 Global Vaccine Adjuvants Market Outlook, By Oral (2022-2030) ($MN)
  • Table 26 Global Vaccine Adjuvants Market Outlook, By Intradermal (2022-2030) ($MN)
  • Table 27 Global Vaccine Adjuvants Market Outlook, By Application (2022-2030) ($MN)
  • Table 28 Global Vaccine Adjuvants Market Outlook, By Research Application (2022-2030) ($MN)
  • Table 29 Global Vaccine Adjuvants Market Outlook, By Commercial Application (2022-2030) ($MN)
  • Table 30 Global Vaccine Adjuvants Market Outlook, By End User (2022-2030) ($MN)
  • Table 31 Global Vaccine Adjuvants Market Outlook, By Human Vaccine Adjuvants (2022-2030) ($MN)
  • Table 32 Global Vaccine Adjuvants Market Outlook, By Veterinary Vaccine Adjuvants (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.